Compare Heron Therapeutics Inc (HRTX) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Nasdaq Inc — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Nasdaq Inc trades at $93.65 (market cap $51.63B). The key difference: Nasdaq Inc is far larger — about 759.2× Heron Therapeutics Inc's market cap, and Nasdaq Inc pays a 1.26% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Nasdaq Inc for 126 Days on average.
| HRTX | NDAQ | |
|---|---|---|
Market Cap | $68.01M | $51.63B |
Volume | 1,891,941 | 2,668,175 |
Sector | Health | Financials |
52-Week High | $1.49 | $100.98 |
52-Week Low | $0.27 | $76.85 |
Typical Hold Time | 35 Days | 126 Days |
Enterprise Value | $174.75M | $58.09B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
Nasdaq Inc. (NDAQ) trades at $92.37, up 0.48% today, with a bullish technical signal from moving averages and strong fundamental performance including a 21.64% net income margin and consistent earnings beats. Recent news highlights growth in its Financial Technology business, such as HSBC adopting Nasdaq Calypso for derivatives clearing (GlobeNewsWire, 2026-09-28).
The outlook is positive with a consensus price target of $110.43, implying 19.6% upside, supported by robust profitability and AI-driven initiatives. Risks include high valuation multiples and market volatility, but analyst sentiment is strongly bullish with 61% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
